Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK1120212B (Standard DMSO content)
GSK1120212B · 1 trial · 1 indication
Pharmacokinetic data will include corrected maximum plasma concentration (Cmax) of GSK1120212B. Comparison of Cmax will enable to determine the relative bioavailability of the test formulation with lower DMSO content (Treatment B) and the standard reference formulation (Treatment A). Period 2 PK parameters will be corrected for residual concentrations from Period 1 (based on individual estimates of t1/2) to remove the carry-over effect.
Pharmacokinetic data will include corrected area under the time-concentration curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)) and AUC from zero to infinity (AUC(0-inf)) of GSK1120212B. Period 2 PK parameters will be corrected for residual concentrations from Period 1 (based on individual estimates of t1/2) to remove the carry-over effect.
Pharmacokinetic data will include corrected time of occurrence of Cmax (tmax) of GSK1120212B. Period 2 PK parameters will be corrected for residual concentrations from Period 1 (based on individual estimates of t1/2) to remove the carry-over effect.
| Arm | Type | Description |
|---|---|---|
| Treatment A: GSK1120212B (Standard DMSO content) | EXPERIMENTAL | Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water. |
| Treatment B: GSK1120212B (Lower DMSO content) | EXPERIMENTAL | Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water. |
| Name | Type | Description |
|---|---|---|
| GSK1120212B (Standard DMSO content) | DRUG | Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%. |
| GSK1120212B (Lower DMSO content) | DRUG | Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%. |
Inclusion Criteria: * Has provided signed, written informed consent. * Male or female, age \>=18 years of age at the time of signing the informed consent form. * Has histologically or cytologically confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapy (ies) or f...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
GSK1120212B is an investigational small molecule in Phase 1 development at GSK plc for cancer. It is a MEK inhibitor, studied in solid tumor malignancies. The compound has been evaluated in a single completed Phase 1 trial in the United States. It is not an approved therapy and remains in clinical development.
GSK1120212B targets MEK, a kinase in the MAPK signaling pathway. It is described as a MEK inhibitor. By targeting MEK, the drug is designed to interfere with signaling that drives tumor cell growth in solid tumors. The Phase 1 study of GSK1120212B was conducted in subjects with solid tumor malignancies.
GSK1120212B is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 study of the compound in patients with solid tumor malignancies. GSK plc is the developer of record for this MEK inhibitor asset.
GSK1120212B is in Phase 1 development. It has been studied in one completed Phase 1 trial in cancer. The drug is investigational and has not been approved for any indication. No active trials of GSK1120212B are currently listed.
GSK1120212B has been studied in one clinical trial, NCT01725100, titled A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies. That Phase 1 trial enrolled 80 participants in the United States and is completed. It was controlled and randomized, without double blinding.
Yes. GSK1120212B is also known as GSK1120212B (Standard DMSO content). The parenthetical refers to the standard DMSO content form of the compound. Both names refer to the same investigational MEK inhibitor developed by GSK plc for cancer.